You are here: Industry Insights > Liquid Biopsy

News List

World Liquid Biopsy Markets Report 2021: Liquid Biopsy Progress Delayed by COVID Pandemic but Huge Cancer Screening Opportunity Still Looms - Forecast to 2025 prnewswire
October 13, 2021
The "Liquid Biopsy Markets by Cancer Type and by Usage Type with Impact of COVID-19 Pandemic. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2021-2025" report...
Research backs use of liquid biopsy for personalised cancer care pharmatimes
September 14, 2020
UK research has shown that a blood test is able to identify various mutations in advanced breast cancer and can thus match women to targeted treatment, adding further weight to evidence backing use of liquid biopsies for more personalised cancer care.
Study demonstrates Clinical Utility of Liquid Biopsy for Cancer Monitoring biospectrumasia
May 20, 2019
Multi-institutional clinical research indicates liquid biopsy can detect changes in tumor profile and resistance to treatment
Guardant to develop CDx and TMB liquid biopsy tests for AstraZeneca’s targeted cancer therapies fiercebiotech
December 26, 2018
AstraZeneca has tapped Guardant Health to develop blood-based companion diagnostics for its cancer treatments Tagrisso and Imfinzi.....
Proteome blood test developer Seer emerges with $36M in funding fiercebiotech
December 26, 2018
Seer, a liquid biopsy company aimed at querying the body’s proteome, has emerged from stealth with $36 million in funding to develop early-warning tests for cancer and neurological diseases.
GENETRON 3D gets launch approval to ease liquid biopsy of tumor biospectrumasia
August 23, 2018
The launch approval is helpful for Genetron Health to enhance development and innovation for tumor liquid biopsy, and provide support for the healthy development of the oncogene detection industry
Study using Biocartis’ liquid biopsy assay shows new option for melanoma retreatment europeanpharmaceuticalreview
March 20, 2017
In a new study, advanced metastatic melanoma cancer patients that had become resistant to their BRAF-targeted treatment were successfully given a retreatment with that same therapy following a three months pause after resistance confirmation.